

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

PE anti-human CD8

RRID:AB_1953243

Type: Antibody

Proper Citation

BioLegend Cat# 344705, RRID:AB_1953243

Antibody Information

URL: http://antibodyregistry.org/AB_1953243

Proper Citation: BioLegend Cat# 344705, RRID:AB_1953243

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_1953243

Vendor: BioLegend

Catalog Number: 344705

Alternative Catalog Numbers: 344706

Record Creation Time: 20250819T220105+0000

Record Last Update: 20250820T005039+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD8.

No alerts have been found for PE anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang X, et al. (2025) An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis. *Cell*, 188(16), 4225.

Barra JM, et al. (2024) Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. *Cell reports*, 43(11), 114994.

Toader D, et al. (2023) Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. *Molecular cancer therapeutics*, 22(9), 999.

Leite NC, et al. (2020) Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells. *Cell reports*, 32(2), 107894.